Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer.

Capper CP, Rae JM, Auchus RJ.

Horm Cancer. 2016 Jun;7(3):149-64. doi: 10.1007/s12672-016-0259-0. Epub 2016 Mar 11. Review.

2.

Inhibition of angiogenesis by selective estrogen receptor modulators through blockade of cholesterol trafficking rather than estrogen receptor antagonism.

Shim JS, Li RJ, Lv J, Head SA, Yang EJ, Liu JO.

Cancer Lett. 2015 Jun 28;362(1):106-15. doi: 10.1016/j.canlet.2015.03.022. Epub 2015 Mar 20.

3.

MicroRNA-574-3p, identified by microRNA library-based functional screening, modulates tamoxifen response in breast cancer.

Ujihira T, Ikeda K, Suzuki T, Yamaga R, Sato W, Horie-Inoue K, Shigekawa T, Osaki A, Saeki T, Okamoto K, Takeda S, Inoue S.

Sci Rep. 2015 Jan 6;5:7641. doi: 10.1038/srep07641.

4.

MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.

Ward A, Shukla K, Balwierz A, Soons Z, König R, Sahin O, Wiemann S.

J Pathol. 2014 Aug;233(4):368-79. doi: 10.1002/path.4363. Epub 2014 Jun 2.

5.

Estrogenic environmental chemicals and drugs: mechanisms for effects on the developing male urogenital system.

Taylor JA, Richter CA, Ruhlen RL, vom Saal FS.

J Steroid Biochem Mol Biol. 2011 Oct;127(1-2):83-95. doi: 10.1016/j.jsbmb.2011.07.005. Epub 2011 Jul 30. Review.

6.

An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors.

Huang L, Zhao S, Frasor JM, Dai Y.

PLoS One. 2011;6(7):e22274. doi: 10.1371/journal.pone.0022274. Epub 2011 Jul 15.

7.

Regulation of cell cycle and RNA transcription genes identified by microarray analysis of PC-3 human prostate cancer cells treated with luteolin.

Shoulars K, Rodriguez MA, Thompson T, Markaverich BM.

J Steroid Biochem Mol Biol. 2010 Jan;118(1-2):41-50. doi: 10.1016/j.jsbmb.2009.09.016. Epub 2009 Oct 27.

8.

Construction and characterization of a doxycycline-inducible transgenic system in Msx2 expressing cells.

Lin C, Yin Y, Chen H, Fisher AV, Chen F, Rauchman M, Ma L.

Genesis. 2009 May;47(5):352-9. doi: 10.1002/dvg.20506.

9.

Tamoxifen resistance and epigenetic modifications in breast cancer cell lines.

Badia E, Oliva J, Balaguer P, Cavaillès V.

Curr Med Chem. 2007;14(28):3035-45. Review.

10.

The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer.

Bosco EE, Wang Y, Xu H, Zilfou JT, Knudsen KE, Aronow BJ, Lowe SW, Knudsen ES.

J Clin Invest. 2007 Jan;117(1):218-28. Epub 2006 Dec 7.

11.

Large effects from small exposures. I. Mechanisms for endocrine-disrupting chemicals with estrogenic activity.

Welshons WV, Thayer KA, Judy BM, Taylor JA, Curran EM, vom Saal FS.

Environ Health Perspect. 2003 Jun;111(8):994-1006. Review.

12.

An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens.

Montano MM, Ekena K, Delage-Mourroux R, Chang W, Martini P, Katzenellenbogen BS.

Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6947-52.

13.

Identification of BCAR3 by a random search for genes involved in antiestrogen resistance of human breast cancer cells.

van Agthoven T, van Agthoven TL, Dekker A, van der Spek PJ, Vreede L, Dorssers LC.

EMBO J. 1998 May 15;17(10):2799-808.

14.

Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor.

Gehm BD, McAndrews JM, Chien PY, Jameson JL.

Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):14138-43.

15.

Effect of estrogen upon cyclic ADP ribose metabolism: beta-estradiol stimulates ADP ribosyl cyclase in rat uterus.

Chini EN, de Toledo FG, Thompson MA, Dousa TP.

Proc Natl Acad Sci U S A. 1997 May 27;94(11):5872-6.

16.

Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice.

Bourassa PA, Milos PM, Gaynor BJ, Breslow JL, Aiello RJ.

Proc Natl Acad Sci U S A. 1996 Sep 17;93(19):10022-7.

17.
18.

The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways.

Beck CA, Weigel NL, Moyer ML, Nordeen SK, Edwards DP.

Proc Natl Acad Sci U S A. 1993 May 15;90(10):4441-5.

20.

Tamoxifen blocks chloride channels. A possible mechanism for cataract formation.

Zhang JJ, Jacob TJ, Valverde MA, Hardy SP, Mintenig GM, Sepúlveda FV, Gill DR, Hyde SC, Trezise AE, Higgins CF.

J Clin Invest. 1994 Oct;94(4):1690-7.

Supplemental Content

Support Center